A5003818954- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- PI3K/AKT/mTOR signaling in cancer
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Peptidase Inhibition and Analysis
- Cancer Cells and Metastasis
- CAR-T cell therapy research
- Monoclonal and Polyclonal Antibodies Research
- Cancer Mechanisms and Therapy
- Lung Cancer Diagnosis and Treatment
- Metastasis and carcinoma case studies
- Acute Lymphoblastic Leukemia research
- Cancer Immunotherapy and Biomarkers
- Immunodeficiency and Autoimmune Disorders
- Infectious Diseases and Mycology
- Synthesis and biological activity
- Biochemical and Molecular Research
- Nonmelanoma Skin Cancer Studies
- Cell death mechanisms and regulation
- Melanoma and MAPK Pathways
- Cancer therapeutics and mechanisms
- Hedgehog Signaling Pathway Studies
Deutschen Konsortium für Translationale Krebsforschung
2020
Centre Antoine Lacassagne
2017
Array BioPharma (United States)
2013
Prince Charles Hospital
2012
Royal Brisbane and Women's Hospital
2012
Peter MacCallum Cancer Centre
2012
Genentech
2010-2012
NeuroDevelopment Center
2009
Venetoclax inhibits BCL2, an antiapoptotic protein that is pathologically overexpressed and central to the survival of chronic lymphocytic leukemia cells. We evaluated efficacy venetoclax in combination with rituximab patients relapsed or refractory leukemia.In this randomized, open-label, phase 3 trial, we randomly assigned 389 receive for up 2 years (from day 1 cycle 1) plus first 6 months (venetoclax-rituximab group) bendamustine (bendamustine-rituximab group). The trial design did not...
The pathways underlying basal-like breast cancer are poorly understood, and as yet, there is no approved targeted therapy for this disease. We investigated the role of mitogen-activated protein kinase (MEK) phosphatidylinositol 3-kinase (PI3K) inhibitors therapies cancer.We used pharmacogenomic analysis a large panel cell lines with detailed accompanying molecular information to identify predictors response potent selective inhibitor MEK also define mechanisms combined PI3K targeting in...
Elevated levels or increases in circulating tumor cells (CTC) portend poor prognosis patients with epithelial cancers. Less is known about CTCs as surrogate endpoints their use for predictive biomarker evaluation. This study investigated the utility of CTC enumeration and characterization using CellSearch platform, well mutation detection DNA (ctDNA), advanced non-small cell lung cancer (NSCLC).Forty-one were enrolled a single-arm phase II clinical trial erlotinib pertuzumab. Peripheral...
Background Evaluation of cancer biomarkers from blood could significantly enable biomarker assessment by providing a relatively non-invasive source representative tumor material. Circulating Tumor Cells (CTCs) isolated metastatic patients hold significant promise in this regard. Methodology/Principal Findings Using spiked tumor-cells we evaluated CTC capture on different technology platforms, including CellSearch® and two biochip used the CTCs to develop optimize assays for molecular...
BCL-2 family proteins dictate survival of human multiple myeloma cells, making them attractive drug targets. Indeed, cells are sensitive to antagonists that selectively target prosurvival such as BCL-2/BCL-XL (ABT-737 and ABT-263/navitoclax) or only (ABT-199/GDC-0199/venetoclax). Resistance these three drugs is mediated by expression MCL-1. However, given the selectivity profile venetoclax it unclear whether coexpression BCL-XL also affects antitumor responses in myeloma. In cell lines (n =...
Purpose The MURANO study demonstrated significant progression-free survival (PFS) benefit for fixed-duration venetoclax-rituximab compared with bendamustine-rituximab in relapsed/refractory chronic lymphocytic leukemia. With all patients off treatment, we report minimal residual disease (MRD) kinetics and updated outcomes. Methods Patients were randomly assigned to 2 years of venetoclax plus rituximab during the first six cycles, or cycles bendamustine-rituximab. Primary end point was PFS....
We describe the preclinical pharmacology and antitumor activity of GDC-0068, a novel highly selective ATP-competitive pan-Akt inhibitor currently in clinical trials for treatment human cancers.The effect GDC-0068 on Akt signaling was characterized using specific biomarkers pathway, response to evaluated cancer cell lines xenograft models with various genetic backgrounds, either as single agent or combination chemotherapeutic agents.GDC-0068 blocked both cultured tumor evidenced by...
Abstract Purpose: The class I phosphatidylinositol 3′ kinase (PI3K) plays a major role in proliferation and survival wide variety of human cancers. A key factor successful development drugs targeting this pathway is likely to be the identification responsive patient populations with predictive diagnostic biomarkers. This study sought identify candidate biomarkers response selective PI3K inhibitor GDC-0941. Experimental Design: We used large panel breast cancer cell lines vivo xenograft...
In previous analyses of the MURANO study, fixed-duration venetoclax plus rituximab (VenR) resulted in improved progression-free survival (PFS) compared with bendamustine (BR) patients relapsed or refractory chronic lymphocytic leukemia (CLL). At 4-year follow-up, we report long-term outcomes, response to subsequent therapies, and predictive value molecular genetic characteristics.Patients CLL were randomly assigned 2 years (VenR for first six cycles) cycles BR. PFS, overall (OS),...
BackgroundExpression of PD-L1 in tumor cells and tumor-infiltrating immune has been associated with improved efficacy to anti-PD-1/PD-L1 inhibitors patients advanced-stage non-small-cell lung cancer (NSCLC) emerged as a potential biomarker for the selection immunotherapies. We investigated utility circulating (CTCs) white blood (WBCs) noninvasive method evaluate status advanced NSCLC patients.Patients methodsCTCs WBCs were enriched from peripheral samples (ISET® platform; Rarecells) 106...
We evaluated the safety and biologic activity of BH3 mimetic protein, navitoclax, combined with rituximab, in comparison to rituximab alone. One hundred eighteen patients chronic lymphocytic leukemia (CLL) were randomized receive eight weekly doses (arm A), plus daily navitoclax for 12 weeks B) or until disease progression unacceptable toxicity C). Investigator-assessed overall response rates (complete [CR] partial [PR]) 35% 55% B, p = 0.19 vs. A) 70% C, 0.0034 A). Patients del(17p) high...
PTEN gene loss occurs frequently in castration-resistant prostate cancer (CRPC) and may drive progression through activation of the PI3K/AKT pathway. Here, we developed a novel CTC-based assay to determine status examined correlation between CTCs matched tumour tissue samples. was evaluated on an enrichment-free platform (Epic Sciences) by fluorescence situ hybridisation (FISH). archival fresh FISH immunohistochemistry. Peripheral blood collected from 76 patients. Matched available for 48...
Key Points Low mutation load is associated with a benefit from rituximab maintenance. The Teff signature correlates high load, prognostic, and may distinguish immunologically distinct FL subgroups.
Deregulation of apoptosis is a common occurrence in cancer, for which emerging oncology therapeutic agents designed to engage this pathway are undergoing clinical trials. With the aim uncovering strategies activate cancer cells, we used pooled shRNA screen interrogate death receptor signaling. This screening approach identified 16 genes that modulate sensitivity ligand induced apoptosis, with several exhibiting frequent overexpression and/or copy number gain cancer. Interestingly, two top...
// Marius Ilie 1, 2, * , Edith Szafer-Glusman 3, Véronique Hofman 4 Elodie Long-Mira 2 Rebecca Suttmann 3 Walter Darbonne Catherine Butori 1 Salomé Lalvée Julien Fayada Eric Selva Wei Yu Charles-Hugo Marquette 5 David S. Shames Elizabeth Punnoose Paul Laboratory of Clinical and Experimental Pathology Liquid Biopsy Laboratory, Pasteur Hospital, University Hospital Federation OncoAge, Université Côte d'Azur, Nice, France Institute for Research on Cancer Ageing, Nice (IRCAN), INSERM U1081/UMR...